1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen Inc.(NasdaqGS:BIIB) dropped from Russell Top 200 Value Index

06/24/2022 | 12:00am EDT

Biogen Inc.(NasdaqGS:BIIB) dropped from Russell Top 200 Value Index


© S&P Capital IQ 2022
All news about BIOGEN INC.
08/03Eisai presents new findings on lecanemab's investigational subcutaneous formulation and..
PR
07/28The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BII..
GL
07/28The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BII..
AQ
07/27Biogen Inc. - FDA Accepts Biogen's New Drug Application and Grants Priority Review of T..
AQ
07/26Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi..
MT
07/26Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi..
MT
07/26U.S. FDA accepts Biogen's ALS therapy for review
RE
07/26U.S. FDA grants priority review to Biogen's ALS drug
RE
07/26FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a ..
GL
07/26Biogen Inc. Announces FDA Accepts its New Drug Application and Grants Priority Review o..
CI
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 9 995 M - -
Net income 2022 2 350 M - -
Net cash 2022 11,0 M - -
P/E ratio 2022 13,8x
Yield 2022 -
Capitalization 31 664 M 31 664 M -
EV / Sales 2022 3,17x
EV / Sales 2023 3,04x
Nbr of Employees 9 610
Free-Float 85,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 218,20 $
Average target price 238,38 $
Spread / Average Target 9,25%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP